MacroGenics Inc., headquartered in Rockville, Maryland, disclosed a loss of $36.3 million during the second quarter, translating to a loss of 57 cents per share. Despite this, the company outperformed predictions from Wall Street analysts. The consensus view from five analysts surveyed by Zacks Investment Research had anticipated a loss of 59 cents per share, making MacroGenics’ actual performance better than expected.
In terms of revenue, MacroGenics posted $22.2 million in the period, exceeding the expectations set by analysts. Forecasts from four analysts surveyed by Zacks had predicted revenue of $21.2 million. This positive revenue performance further underscored the company’s strong showing in the second quarter.
The information in this report was generated by Automated Insights using data provided by Zacks Investment Research. For more detailed insights, interested individuals can access the Zacks stock report on MGNX by visiting their website. MacroGenics’ financial results in the second quarter indicate a resilient performance amidst market expectations.
Key Takeaways:
– MacroGenics Inc. reported a loss of $36.3 million in the second quarter, surpassing Wall Street expectations.
– The company posted revenue of $22.2 million, which exceeded Street forecasts.
– This financial performance demonstrates MacroGenics’ resilience and stability in the biopharmaceutical sector.
– For further details and analysis, individuals can refer to the Zacks stock report on MGNX for a comprehensive overview of MacroGenics Inc.’s financial standing.
Read more on chron.com